ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City
MWN-AI** Summary
ROTH Capital Partners, LLC will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan Club in New York City. This invite-only event aims to connect C-suite executives from both public and private healthcare companies with leading institutional investors and sector specialists. Participants in this year's conference will represent crucial subsectors including Biotechnology, Medical Technologies, Biopharmaceuticals, and Pharmaceuticals.
The conference's structure allows for 25-minute 1-on-1 and small group meetings between executives and ROTH's institutional clients, fostering in-depth discussions about business roadmaps, investment strategies, and potential collaborations.
The event will kick off with a Breakfast Panel titled "Small Firms Tackling Blockbuster Indications," where companies like CRVO and RVPH will present their drug development experiences and highlight sector-specific challenges and opportunities. Furthermore, attendees can participate in three additional panel discussions during the day, covering topics such as novel therapies for Acute Myeloid Leukemia (AML), regulatory discussions with FDA experts, and breakthrough technologies shaping future innovations.
James Antonopoulos, Managing Director at ROTH, emphasized the heightened demand for healthcare innovation due to factors like demographic shifts and advancements in technology. Jonathan Aschoff, Senior Research Analyst at ROTH, noted that opportunities for smaller-cap healthcare companies are improving, especially with a favorable interest rate environment.
The conference will close with a Cocktail Reception, offering a relaxed atmosphere for networking and relationship building. Interested participants are encouraged to reach out to their ROTH representatives to confirm attendance. ROTH has been a significant player in the healthcare sector since 2010, completing over 600 transactions valued at more than $25 billion.
MWN-AI** Analysis
ROTH Capital Partners is set to host its 4th Annual Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan Club in New York City. This annual event gathers executives from public and private healthcare companies, institutional investors, and sector specialists, providing a prime platform for deal-making and investment exploration.
As interest rates begin to decline, market sentiment for smaller-cap healthcare companies appears to be shifting positively. This environment should attract investors seeking companies that offer innovative therapies, especially amidst a backdrop of increasing demand for healthcare innovation driven by demographic shifts and advancements in technology. ROTH’s focus on sectors like Biotechnology, Medical Technologies, and Pharmaceuticals positions participants well for discovering lucrative investment opportunities.
The conference features insightful panel discussions and opportunities for one-on-one meetings with executives from notable companies such as Aptevo Therapeutics, Capricor Therapeutics, and Immunic, which can provide in-depth understanding of therapeutic advancements and potential market trajectories. This intimate setting enhances networking opportunities, fostering synergies that may translate into partnerships or investment chances.
Investors looking to capitalize on the evolving healthcare landscape should consider attending this invite-only event. Engaging with industry leaders and gaining direct insights into emerging therapies and technologies can be pivotal for constructing a forward-looking investment portfolio.
Furthermore, as highlighted by ROTH’s Managing Director James Antonopoulos and Senior Research Analyst Jonathan Aschoff, the potential for attractive exits remains high for companies developing value-added therapies, given the interest from larger healthcare entities eager to invest for pipeline enhancement.
Overall, the conference represents a strategic venue for savvy investors to uncover high-potential opportunities in the evolving healthcare ecosystem. Interested attendees should contact ROTH to secure their invitation and join the conversation around healthcare innovation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com , is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan Club, New York City, NY.
The Annual ROTH Healthcare Opportunities Conference will once again bring together C-suite executives from innovative public and private healthcare companies, alongside leading institutional investors and sector specialists exploring new opportunities. This year’s participating companies will span key subsectors including Biotechnology, Medical Technologies, Biopharmaceuticals, and Pharmaceuticals.
This exclusive, invite-only event will feature 1x1/small group meetings between company executives and ROTH’s institutional clients. These 25-minute meetings offer a valuable opportunity for participants to engage in deep discussions about company roadmaps, explore synergies, understand investment strategies, and lay the groundwork for potential collaborations.
The conference will commence with a Breakfast Panel titled "Small Firms Tackling Blockbuster Indications", moderated by Boobalan Pachaiyappan, Ph.D. , Managing Director, Sr. Research Analyst. During this session, participating companies (CRVO, NWRN.SW, RVPH) will share their drug development experience while highlighting industry, sector and indication-specific opportunities and challenges.
In addition to the breakfast panel, attendees will have the opportunity to attend three additional Panel Discussions covering cutting-edge topics in healthcare innovation:
- Novel AML Therapies Showing Clear Clinical Progress (moderator: Jonathan Aschoff, Ph.D. ; participating companies: APVO, MBRX)
- Embracing New Uncertainty: A Round Table Discussion with an FDA Expert: Paul Kim J.D. (moderator: Boobalan Pachaiyappan, Ph.D. ; participating companies: CAPR, CING, PYPD)
- Breakthrough Technologies Spearheading the Next Wave of Innovation (moderator: Boobalan Pachaiyappan, Ph.D. ; participating companies: IMUX, LGVN, OVID)
The single-day event is designed to optimize business efficiency, offering attendees high-power networking opportunities, access to educational content, and pathways to develop partnerships and investment opportunities.
James Antonopoulos , Managing Director, Head of Healthcare Investment Banking at ROTH, stated, “Demand for healthcare innovation has been surging, both in the public and private sectors. The shift is being driven by multiple factors such as changing demographics, advancements in big data and artificial intelligence, and the introduction of new therapeutic and digital solutions. Our conference provides a unique platform for deal discovery, expanding market reach, and forming high-potential partnerships.”
Jonathan Aschoff, Ph.D. , Managing Director, Senior Research Analyst, Biotechnology at ROTH, added, "We believe that the investment environment is finally beginning to improve for smaller cap healthcare companies, especially with interest rates beginning to decrease and the expectation of further near-term decreases. Regardless of market sentiment, companies developing value-added therapies will almost always attract the attention of larger, deep-pocketed healthcare companies that need a pipeline, which almost always provides for a highly favorable investor exit. We look forward to providing access to management through disease-focused panel discussions and individual meetings.”
At the closing of the conference, all attendees are invited to a Cocktail Reception, offering a relaxed environment to foster rapport and build lasting relationships.
The conference is exclusively for ROTH’s institutional clients and is by invitation only. Prospective attendees are encouraged to contact their ROTH sales representative or email registration@roth.com to express interest and confirm participation.
Since 2010, ROTH has been involved in over 600 transactions for its Healthcare clients, with a total transaction value of over $25 Billion. (Source: Roth 09/12/2025)
THURSDAY | OCTOBER 9, 2025
| 7:00am – 8:00am | Registration and Morning Coffee |
| 8:00am – 8:55am | Small Firms Tackling Blockbuster Indications |
| 8:00am – 5:00pm | 1-on-1 / Small Group Meetings and Panel Discussions |
| 10:00am – 10:55am | Novel AML Therapies Showing Clear Clinical Progress |
| 12:00pm – 12:55pm | Embracing New Uncertainty: A Round Table Discussion with an FDA Expert: Paul Kim J.D. |
| 2:00pm – 2:55pm | Breakthrough Technologies Spearheading the Next Wave of Innovation |
| 4:30pm – 6:00pm | Cocktail Reception |
All times are listed in Eastern Time (ET)
VENUE
Metropolitan Club
1 East 60th St. off 5th Ave.
New York, NY 10022
Participating Companies at the time of this release include:
| Company Name | Mobile Friendly URL |
| Allurion Technologies, Inc. (ALUR) | https://www.allurion.com/en |
| Aptevo Therapeutics Inc. (APVO) | https://aptevotherapeutics.com/ |
| Beyond Air, Inc. (XAIR) | https://www.beyondair.net/ |
| Capricor Therapeutics, Inc. (CAPR) | https://www.capricor.com/ |
| CapsoVision, Inc. (CV) | https://capsovision.com/ |
| Cardiol Therapeutics, Inc. (CRDL) | https://www.cardiolrx.com/ |
| CervoMed Inc. (CRVO) | https://www.cervomed.com/ |
| Cingulate Inc. (CING) | https://www.cingulate.com/ |
| Electromed, Inc. (ELMD) | https://smartvest.com/ |
| GeoVax Labs, Inc. (GOVX) | https://www.geovax.com/ |
| Heartbeam, Inc. (BEAT) | https://www.heartbeam.com/ |
| Immunic, Inc. (IMUX) | https://imux.com/ |
| InfuSystems Holdings, Inc. (INFU) | https://infusystem.com/ |
| Journey Medical Corporation (DERM) | https://journeymedicalcorp.com/ |
| LifeMD, Inc. (LFMD) | https://www.lifemd.com/ |
| Longeveron Inc. (LGVN) | https://longeveron.com/ |
| Medicenna Therapeutics Corp. (TSX: MDNA) | https://www.medicenna.com/ |
| Moleculin Biotech, Inc. (MBRX) | https://moleculin.com/ |
| Newron Pharmaceuticals S.p.A. (XSWX: NWRN) | https://www.newron.com/ |
| Nuo Therapeutics, Inc. (AURX) | https://www.nuot.com/ |
| Nuvectis Pharma, Inc. (NVCT) | https://nuvectis.com/ |
| Ovid Therapeutics Inc. (OVID) | https://ovidrx.com/ |
| PolyPid Ltd. (PYPD) | https://www.polypid.com/ |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | https://revivapharma.com/ |
| Sanuwave Health, Inc. (SNWV) | https://sanuwave.com/ |
| Stereotaxis, Inc. (STXS) | https://www.stereotaxis.com/ |
| Traws Pharma, Inc. (TRAW) | https://www.trawspharma.com/ |
| vTv Therapeutics, Inc. (VTVT) | https://vtvtherapeutics.com/ |
| Xtant Medical Holdings, Inc. (XTNT) | https://xtantmedical.com/ |
List as of 09/30/2025 – subject to change
For b2i company profiles – https://b2idigital.com/4th-annual-roth-healthcare-opportunities-conference
Thank you to the event sponsors:
Pryor Cashman
NSI Insurance Group
B2I Digital, Inc.
IBN (InvestorBrandNetwork)
NGO Sustainability Inc.
Centri Business Consulting, LLC
Alliance Advisors
About ROTH
ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately held, employee-owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com .
Investor Contact:
ROTH
Isabel Mattson-Pain
Managing Director, Chief Marketing Officer
949.720.7117, imattson-pain@roth.com
ROTH – Member FINRA/SIPC – www.roth.com
Media Contact:
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717, Editor@InvestorBrandNetwork.com
FAQ**
What strategic insights can Medicenna Therapeutics Corp. (MDNA:CC) share during the ROTH Healthcare Opportunities Conference regarding its recent drug development initiatives and how they align with market demands?
How does Medicenna Therapeutics Corp. (MDNA:CC) plan to leverage the networking opportunities at the ROTH Conference to foster partnerships with institutional investors in the biotechnology sector?
What are the anticipated challenges for Medicenna Therapeutics Corp. (MDNA:CC) in the current healthcare landscape, as discussed during the "Small Firms Tackling Blockbuster Indications" panel at the ROTH Conference?
In what ways can attending the ROTH Healthcare Opportunities Conference benefit Medicenna Therapeutics Corp. (MDNA:CC) in terms of investor relations and potential growth strategies in the industry?
**MWN-AI FAQ is based on asking OpenAI questions about Medicenna Therapeutics Corp. (TSXC: MDNA:CC).
NASDAQ: MDNA:CC
MDNA:CC Trading
-3.81% G/L:
$2.02 Last:
23,946 Volume:
$2.10 Open:
